Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
Applied Optoelectronics
AAOI
$12.7B
| $751K | ﹤0.01% |
+63,200
| New | +$674K |
|
2752
MarineMax
HZO
$1.15B
| $751K | ﹤0.01% |
+45,000
| New | +$734K |
|
2753
Energy Recovery
ERII
$407M
| $747K | ﹤0.01% |
76,300
-22,900
| -23% | -$211K |
|
2754
Gaia
GAIA
$35.3M
| $742K | ﹤0.01% |
92,900
-38,600
| -29% | -$298K |
|
2755
Lands' End
LE
$383M
| $738K | ﹤0.01% |
43,900
-49,270
| -53% | -$645K |
|
2756
FreightCar America
RAIL
$242M
| $738K | ﹤0.01% |
356,584
+221,300
| +164% | +$664K |
|
2757
iShares Global Tech ETF
IXN
$9.45B
| $737K | ﹤0.01% |
21,012
+14,412
| +218% | +$473K |
|
2758
Lipocine
LPCN
$17.6M
| $732K | ﹤0.01% |
111,839
+76,029
| +212% | +$1.95M |
|
|
KG
2759
Kestrel Group
KG
$60.5M
| $732K | ﹤0.01% |
48,820
+545
| +1% | +$7.31K |
|
|
IFLN
2760
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$307M
| $732K | ﹤0.01% |
38,000
-14,094
| -27% | -$269K |
|
2761
Emerson Radio
MSN
$8.1M
| $731K | ﹤0.01% |
890,950
+4,300
| +0.5% | +$3.69K |
|
2762
Cineverse
CNVS
$68.7M
| $726K | ﹤0.01% |
51,841
+315
| +0.6% | +$5.42K |
|
|
RBNC
2763
DELISTED
Reliant Bancorp, Inc. Common Stock
RBNC
| $726K | ﹤0.01% |
32,625
+14,600
| +81% | +$329K |
|
2764
FVCBankcorp
FVCB
$340M
| $722K | ﹤0.01% |
51,625
+21,750
| +73% | +$301K |
|
2765
Everest Group
EG
$14.1B
| $721K | ﹤0.01% |
2,605
-27,600
| -91% | -$7.28M |
|
2766
Willamette Valley Vineyards
WVVI
$11.5M
| $717K | ﹤0.01% |
103,502
+5,424
| +6% | +$38K |
|
2767
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$724M
| $715K | ﹤0.01% |
16,300
-5,600
| -26% | -$251K |
|
2768
MaxLinear
MXL
$7.54B
| $715K | ﹤0.01% |
33,713
-16,500
| -33% | -$342K |
|
2769
Companhia Siderúrgica Nacional
SID
$1.21B
| $712K | ﹤0.01% |
206,376
-3,952,500
| -95% | -$12.3M |
|
|
OPTN
2770
DELISTED
OptiNose
OPTN
| $711K | ﹤0.01% |
5,140
+2,447
| +91% | +$317K |
|
|
TRIB
2771
Trinity Biotech
TRIB
$8.17M
| $710K | ﹤0.01% |
4,581
+45
| +1% | +$6.42K |
|
|
IEA
2772
DELISTED
Infrastructure and Energy Alternatives, Inc. Common Stock
IEA
| $708K | ﹤0.01% |
219,833
+11,100
| +5% | +$34.4K |
|
|
TBI
2773
Trueblue
TBI
$304M
| $707K | ﹤0.01% |
29,400
-62,600
| -68% | -$1.43M |
|
2774
The Joint Corp
JYNT
$120M
| $704K | ﹤0.01% |
43,588
-27,883
| -39% | -$507K |
|
|
YARW
2775
Yarrow Bioscience, Inc. Common Stock
YARW
$113M
| $704K | ﹤0.01% |
42
+7
| +20% | +$117K |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.